Our new infographic provides a unique view into milestone achievement and new drug successes for biotech/pharma transactions with over $50MM upfront deal value. Built from the SRS Acquiom database of over 130 life sciences deals with more that $24 billion in potential milestone payments (from private-target life sciences M&A transactions from 2008 to 2017), this snapshot from our 2017 SRS Acquiom Life Sciences M&A Study will provide insight into common topics including:

  • Developmental Milestone Achievement by Product Phase
  • Early Stage Success Rate
  • Late Stage Success Rate

 

Related Stories